BioWorld

Jan. 13, 2004

Threshold's Oncology Products Emerge Through $41M Series B

Stepping into the biotech spotlight, cancer drug developer Threshold Pharmaceuticals Inc. raised $41 million in a second round of financing that attracted new and existing investors. (BioWorld Today) Read More

Regeneron CEO: Beware 'Fibs' From Prospective Dealmakers

BioPort Gets Anthrax Vaccine Contract Worth Up To $245M

Concurrent Raises $15M, Partners With Intel On 'Machine Learning'

Inhibitex Series E Raises $20M To Advance Veronate, Aurexis

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...